Price: $0.0000
$0.00
%
|
Day's High:
| 0.00
| Week Perf:
|
|
Day's Low: |
$ 0.00 |
30 Day Perf: |
|
Volume (M): |
0 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
133 |
Employees |
2,040 |
Revenues (TTM) (Millions $) |
664 |
Net Income (TTM) (Millions $) |
-71 |
Cash Flow (TTM) (Millions $) |
-95 |
Capital Exp. (TTM) (Millions $) |
33 |
Akorn Inc
due to regulatory issues, the acquisition was terminated in 2018. Despite numerous legal battles, Akorn has continued to grow its business and expand its portfolio.
In terms of manufacturing capacity, Akorn has numerous state-of-the-art facilities located in the United States, China, India, and Switzerland. Its production facilities are compliant with the strictest quality and safety standards set by various international regulatory bodies such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and the World Health Organization (WHO).
Akorn has also established a strong global distribution network, partnering with leading distributors and wholesalers to ensure timely delivery of its products to customers and patients worldwide. The company has a dedicated team of professionals who are committed to providing high-quality products, outstanding customer service, and delivering effective medical solutions to address the evolving needs of the market.
Overall, Akorn is a leading global pharmaceutical company with a strong brand name, diverse product portfolio, state-of-the-art manufacturing facilities, and a robust global distribution network. The company remains committed to delivering innovative, high-quality, and cost-effective healthcare solutions to healthcare professionals, patients, and the animal health industry worldwide.
Company Address: 1925 W. Field Court, Lake Forest, 60045 IL
Company Phone Number: 279-6100 Stock Exchange / Ticker: AKRXQ
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Affimed N V
/>Affimed N.V., a leading clinical-stage immuno-oncology company, recently released its financial results for the fiscal year 2023. These results highlight a significant decline in revenue and an increased net loss per share compared to the previous year. However, despite the challenging financial performance, Affimed has also provided an update on the promising clinical response data for its AFM24-102 trial in treating EGFRwt NSCLC. This article will explore the potential impact of these financial results and the implications for Affimed's future. Disastrous Financials: In the fiscal fourth quarter of 2023, Affimed N.V. reported a disastrous financial performance, with revenue fading by 79.99% to $9.27 million and a net loss per share widening to $-7.94 from the corresponding quarter a year ago. The company's net deficit for the quarter amounted to $-118.651 million, surpassing the $-96.324 million deficit of the previous year.
|
Pds Biotechnology Corp
The recent financial results of PDS Biotechnology Corp, a clinical-stage immunotherapy company specializing in targeted immunotherapies for cancer and infectious diseases, have garnered interest among industry experts. An analysis of the company's fourth-quarter earnings in 2023 reveals a notable reduction in the operating deficit compared to the previous year. This positive trend indicates that PDS Biotechnology is making significant progress in its business strategy and operational efficiency. Moreover, the company's recent announcement of inducement stock options to their new CFO, Lars Boesgaard, further highlights its commitment to attracting and retaining top talent to support future growth. Improved Financial Performance: In the October to December 31, 2023 reporting period, PDS Biotechnology's operating deficit was recorded at $-10.406961 million, a significant improvement compared to the $-18.821351 million deficit in the same quarter of the previous year. This reduction in deficit is a significant milestone for the company, reflecting its efforts in increasing operational efficiency.
|
Chemomab Therapeutics Ltd
As the October to December 31, 2023 reporting season continues, the Major Pharmaceutical Preparations sector is generating significant attention. Among the prominent players in this sector, Chemomab Therapeutics Ltd recently disclosed its operating deficit for the most recent fiscal period, indicating a clear transition towards profitability. Moreover, the company has achieved a remarkable feat by being granted a new European patent for its groundbreaking monoclonal antibody, CM-101. This patent extension not only strengthens the company's intellectual property portfolio but also highlights the immense potential of CM-101 as a therapeutic solution for liver diseases, particularly Primary Sclerosing Cholangitis (PSC). This article aims to explore the implications of this patent grant and its potential impacts on the future performance of Chemomab Therapeutics. Background: Primary Sclerosing Cholangitis is a chronic liver disease characterized by progressive inflammation and fibrosis of the bile ducts, which could ultimately lead to liver failure. Unfortunately, there are limited treatment options available for PSC patients, creating an urgent need for innovative interventions. In response, Chemomab developed CM-101, a first-in-class monoclonal antibody that has exhibited promising results in preclinical studies. As of now, CM-101 has progressed to Phase 2 of clinical development specifically for the treatment of PSC.
|
Monopar Therapeutics Inc
Investors in the stock market have something to celebrate as the October to December 31, 2023 reporting cycle resumes. Numerous corporations, including those in the Major Pharmaceutical Preparations industry, have announced their earnings, and one company that stands out is Monopar Therapeutics Inc. (Nasdaq: MNPR). Despite facing some challenges, Monopar Therapeutics has shown resilience and determination in its day-to-day operations, resulting in a significant improvement in its financial performance compared to the previous year. In the fourth quarter of 2023, the company reported an operating shortfall of $-1.911988 million, which is a clear improvement over the $-2.896 million reported in the same period of 2022.
|
Casi Pharmaceuticals Inc
Declining business caused an increase in deficit for the fiscal three months ending December 31 2023, Casi Pharmaceuticals Inc s' deficit per share inched up to $-2.02 from $-3.01 where Revenue went down by -21.407 % to $33.88 million from $43.11 million a year ago.
|
Per Share |
Current |
Earnings (TTM) |
-2.78 $ |
Revenues (TTM) |
4.97 $
|
Cash Flow (TTM) |
- |
Cash |
0.62 $
|
Book Value |
-
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-2.78 $
|
Revenues (TTM) |
4.97 $ |
Cash Flow (TTM) |
- |
Cash |
0.62 $
|
Book Value |
- |
Dividend (TTM) |
0 $ |
|
|
|
|